Categories: News

CASIO OBTAINS U.S. FDA CLEARANCE FOR DERMOCAMERA™ AND SCOPE FOR SKIN OBSERVATION

DOVER, N.J., Feb. 15, 2022 /PRNewswire/ — Casio America, Inc., announced today that the U.S. Food and Drug Administration (FDA) has cleared the DZ-D100 DERMOCAMERA™ and the DZ-S50 scope for skin observation as medical devices. The DZ-D100 and DZ-S50 will be available in the U.S. on Casio America’s e-commerce site by March 2022.

Experience the interactive Multichannel News Release here: https://www.multivu.com/players/English/9008951-casio-obtains-us-fda-clearance-dermocamera-scope-skin-observation/

 

Casio began providing the DZ-D100 in Japan in May 2019. The DZ-D100 was developed in collaboration with dermatology professionals and delivers both standard sized and close-up shots of an affected area with a single unit, and can be used with the D’z IMAGE Viewer, a free downloadable software to manage the captured images.

In March 2020, Casio released the DZ-S50 scope, making skin observation even easier. Medical professionals who have introduced these devices in their practice have provided positive feedback, commenting that these Casio products make it simple to take both ordinary or standard sized and close-up shots without switching lenses and noting the ease of making observations since the unit can capture polarized, non-polarized and UV* photos at the same viewpoint with a single click of the shutter button. Casio has been rolling out these innovative medical devices aggressively in markets outside Japan, starting with the launch in Australia and New Zealand in February 2021, where there are high rates of skin disease among the population.

* A 405 nm safelight wavelength is used.

The marketing of certain medical devices in the U.S. requires FDA clearance. The DZ-D100 and DZ-S50 have received FDA Class I clearance. Class I medical devices are devices with low or moderate risk to patient health and safety.

Casio will continue expanding and developing its medical device business both in and outside Japan, seeking to contribute to medical treatment around the world.

About Casio America, Inc.
Casio America, Inc., Dover, N.J., is the U.S. subsidiary of Casio Computer Co., Ltd., Tokyo, Japan, one of the world’s leading manufacturers of consumer electronics and business equipment solutions. Established in 1957, Casio America, Inc. markets calculators, keyboards, digital cameras, mobile presentation devices, disc title and label printers, watches, cash registers and other consumer electronic products. Casio has strived to fulfill its corporate creed of “creativity and contribution” through the introduction of innovative and imaginative products. For more information, visit www.casio.com.

 

 

 

 

 

 

View original content:https://www.prnewswire.com/news-releases/casio-obtains-us-fda-clearance-for-dermocamera-and-scope-for-skin-observation-301482739.html

SOURCE Casio America, Inc.

Staff

Recent Posts

Methodist Le Bonheur Healthcare named among Best in Cancer Care by Money magazine

MEMPHIS, Tenn., July 5, 2024 /PRNewswire/ -- Methodist Le Bonheur Healthcare announced its four Memphis-based adult hospitals…

2 days ago

Hospital PMI® at 55.8%; June 2024 Hospital ISM® Report On Business®

TEMPE, Ariz., July 5, 2024 /PRNewswire/ -- Economic activity in the hospital subsector grew in June…

2 days ago

KORE Helps mCare Digital Launch the Next Generation of Personal Emergency Technology

mCare Digital unveils the mCareWatch MW-241 powered by KORE connectivity ATLANTA, July 5, 2024 /PRNewswire/…

2 days ago

Cosmo Shareholders Approved All Resolutions Proposed by the Board of Directors at Extraordinary General Meeting

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of…

2 days ago

Hitachi’s Holography Electron Microscope Attains Unprecedented Resolution

Image acquisition and defocusing correction techniques enable observations of atomic-scale magnetic fields at never-before-seen resolution…

3 days ago

Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds

Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical…

3 days ago